ДРАЙГИН Денис (US),АНДЕРЕС Кенна (US),ХО Кэролайн Б. (US),БЛИЗЭТ Джошуа Р. (US),ПРОФФИТТ Кристофер Б. (US),О'БРАЙН Шон (US),РАЙС Уильям Г. (US),ОБРАЙН Шон (US)
申请号：
RU2012106518/15
公开号：
RU2012106518A
申请日:
2010.07.07
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. A method of treating or alleviating a neoplastic disorder, comprising administering to a subject in need of such treatment or relief a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or ester thereof, wherein Z is N or CR； each RR, R and R are independently H or optionally substituted C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl , C7-C12 arylalkyl or C6-C12 heteroarylalkyl each group, or each RR, R and R independently represents halogen, CF, CFN, OR, NR, NROR, NRNR, SR, SOR, SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR, CN, COOR, carboxy bioisostere, CONR, OOCR, COR or NO, each R independently is optionally substituted C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl or C6-C12 heteroarylalkyl group, or each R independently is halogen, OR, NR, NROR, NRNR, SR, SOR, SOR, SONR, NRSOR, NRC , NRCOR, CN, COOR, CONR, OOCR, COR or NO, with each R not independently represents H or C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12 arylalkyl or C6-C12 heteroarylalkyl, and two Rs on the same atom or adjacent atoms can be joined to form a 3-8 membered ring, optionally containing one or more N, O or S atoms ； and each R group and each ring formed by two joined R groups together are optionally substituted with one or more substituents selected from halogen1. Способ лечения или облегчения неопластического расстройства, включающий введение субъекту, нуждающемуся в таком лечении или облегчении, терапевтически эффективного количества соединения Формулы Iили его фармацевтически приемлемой соли или эфира,где Zпредставляет собой N или CR；каждый RR, Rи Rнезависимо представ
